verified SJR 0,521 · Q2 • database Scopus / SJR & Web of Science indexed

Hong Kong · AME Publishing Company

workspace_premium Q2 — Oncology lock Subscription

Translational Cancer Research

Translational Cancer Research is a journal indexed in SJR in Oncology and Cancer Research with an H index of 43. It has an SJR impact factor of 0,521 and it has a best quartile of Q2. It has an SJR impact factor of 0,521.

ISSN: 2218-676X

Publisher: AME Publishing Company

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,521 Q2

H-index 43

Acceptance rate pie_chart

35%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,521

H-index

Docs (year)

515

Docs 3y

1248

Total refs

21873

Cites 3y

2139

Citable 3y

1162

Cites/Doc 2y

1.62

Ref/Doc

42.47

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Bone metabolism in Chinese patients after laparoscopic Roux-en-Y gastric bypass

Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis

Data independent acquisition-mass spectrometry (DIA-MS)-based comprehensive profiling of bone metastatic cancers revealed molecular fingerprints to assist clinical classifications for bone metastasis of unknown primary (BMUP)

CRISPR-Cas genome editing tool: a narrow lane of cancer therapeutics with potential blockades

COPB2 promotes metastasis and inhibits apoptosis of lung adenocarcinoma cells through functioning as a target of miR-216a-3p

Computational resources for radiomics

Comparison of safety and efficacy between total endoscopic resection and conventional open surgery for malignant thyroid tumors: a meta-analysis

Clinical significance of serum cystatin C in early evaluation of renal impairment caused by chemotherapy in elderly patients

Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis

Clinical management of vascular lake during transarterial chemoembolization with CalliSpheres drug-eluting beads (DEBs) for the treatment of hepatocellular carcinoma

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer

Cerebral metastases of parathyroid carcinoma: a case report and literature review

SHOW MORE ARTICLES

Candidate genes for predicting the survival of patients with gastric cancer: a study based on The Cancer Genome Atlas (TCGA) database

"Prostate management" under MRI-guidance: 7 years of improvements

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer

B4GALNT1 enhances cell proliferation and growth in oral squamous cell carcinoma via p38 and JNK MAPK pathway

Associations between polymorphisms in genes of base excision repair pathway and lung cancer risk

Assessing the potential association between Epstein-Barr virus and oral squamous cell carcinoma: a systematic review and meta- analysis

Analysis of factors related to N2- or N3-stage breast cancer associated with 1-2 positive sentinel lymph nodes in Chinese patients

Analysis of a pedigree of Peutz-Jeghers syndrome and RET proto-oncogene mutation: one case report and literature review

An operated case of locally advanced thymic atypical carcinoid in anterior mediastinum: a case report

Additional treatment prolonged survival of pulmonary artery sarcoma after surgical resection

A promising treatment option for refractory male primary choriocarcinoma: report of two cases

A nomogram for predicting cancer-specific survival in different age groups for operable gastric cancer: a population-based study

FAQs

Translational Cancer Research has an SJR of 0,521 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Translational Cancer Research is 35%.

Translational Cancer Research

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Translational Cancer Research?

What is the APC / publication cost?

What is the acceptance rate?